DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Pancreatic Fistula After Minimally Invasive Enucleation

Completed

Conditions: Pancreatic Neuroendocrine Tumor
Pancreatic Tumor, Benign
Solid Pseudopapillary Tumor of the Pancreas

First Posted Date: 2024-08-16

Last Posted Date: 2024-11-07

Lead Sponsor: Fudan University

Target Recruit Count: 173

Registration Number: NCT06557408

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China, Shanghai, Shanghai, China

Selective Neck Dissection Versus Modified Neck Dissection in PTC

Phase 3

Not yet recruiting

Conditions: Thyroid Cancer

Interventions: Procedure: Modified neck dissection
Procedure: Lymph node tracer navigated selective neck dissection

First Posted Date: 2024-08-15

Last Posted Date: 2024-08-15

Lead Sponsor: Fudan University

Target Recruit Count: 250

Registration Number: NCT06554652

Locations: 🇨🇳
Fudan Univeristy Shanghai Cancer Center, Shanghai, China

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma

Not Applicable

Not yet recruiting

Conditions: Malignant Melanoma

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 28

Registration Number: NCT06553781

A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: Lutetium [177Lu]-FAP-75

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT06553846

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center;Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Fluzoparib
Drug: Dalpiciclib

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06552858

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

ADC-induced Neurotoxicity Treated with Duloxetine

Phase 2

Recruiting

Conditions: Solid Tumour

Interventions: Drug: duloxetine

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: Fudan University

Target Recruit Count: 37

Registration Number: NCT06551051

Locations: 🇨🇳
Fudan University Cancer center, Shanghai, Shanghai, China

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Phase 2

Not yet recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: T-DXd
Drug: THP

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Fudan University

Target Recruit Count: 242

Registration Number: NCT06548178

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Topotecan
Drug: Toripalimab

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06548763

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: SHR-A2102 or/and HRS-4642
Drug: SHR-A1904 or/and HRS-4642
Drug: SHR-A1811 or/and HRS-4642

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT06547736

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Procedure: Secondary cytoreduction
Drug: Hyperthermic intraperitoneal chemotherapy

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Fudan University

Target Recruit Count: 94

Registration Number: NCT06544460

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy